Publications by authors named "Peter X Adams"

Claim this Profile
P
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction.
James S Mills, Kenneth W Mahaffey, Yuliya Lokhnygina, Jose C Nicolau, Witold Ruzyllo, Peter X Adams

Coron Artery Dis· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
Peter K Smith, Stanton K Shernan, John C Chen, Michel Carrier, Edward D Verrier, Peter X Adams

J Thorac Cardiovasc Surg· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of mobilized peripheral blood CD34(+) cells from patients with severe coronary artery disease as a source of endothelial progenitor cells.
Abba C Zubair, Sunita Malik, Athena Paulsen, Masakazu Ishikawa, Christopher McCoy, Peter X Adams

Cytotherapy· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
Paul W Armstrong, Yuling Fu, Cynthia M Westerhout, Michael P Hudson, Kenneth W Mahaffey, Peter X Adams

J Am Coll Cardiol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library.
Kenneth W Mahaffey, Craig J Reist, Yuling Fu, Sorin J Brener, Pierre Theroux, Peter X Adams

Contemp Clin Trials· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

JAMA· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
Peter K Smith, Michel Carrier, John C Chen, Axel Haverich, Jerrold H Levy, Peter X Adams

Ann Thorac Surg· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients.
Axel Haverich, Stanton K Shernan, Jerrold H Levy, John C Chen, Michel Carrier, Peter X Adams

Ann Thorac Surg· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.
Kenneth W Mahaffey, Frans Van de Werf, Stanton K Shernan, Christopher B Granger, Edward D Verrier, Peter X Adams

Am Heart J· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Paul W Armstrong, Peter X Adams, Hussein R Al-Khalidi, Christian Hamm, David Holmes

Am Heart J· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
Edward D Verrier, Stanton K Shernan, Kenneth M Taylor, Frans Van de Werf, Mark F Newman, Peter X Adams

JAMA· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis